Skip to main content
. 2018 Oct 3;20:222. doi: 10.1186/s13075-018-1718-5

Fig. 1.

Fig. 1

a Distribution of B-cell subsets in healthy control subjects and in patients with immunoglobulin G4-related disease (IgG4-RD) at baseline and after 6 months of glucocorticoid treatment in absolute counts and percentage of CD19+ B lymphocytes. b Memory B cells at baseline and after 6 months of glucocorticoid treatment in absolute counts and as percentage of CD19+ B lymphocytes. Open and filled dots indicate patients showing memory B-cell increase and decrease after treatment, respectively. Results are expressed as mean ± SEM. * p < 0.05; ** p < 0.01. ns Not statistically significant